Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
about
Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonistGlucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studiesAdvances in Clinical Cardiology 2016: A Summary of the Key Clinical Trials.HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysisInterpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach.Newer antidiabetic drugs and calorie restriction mimicry.Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors.United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes.Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.SGLT2 inhibitors in the management of type 2 diabetes.Albiglutide: a unique GLP-1 receptor agonist.A Plethora of GLP-1 Agonists: Decisions About What to Use and When.The safety of albiglutide for the treatment of type 2 diabetes.
P2860
Q26749189-3E3DBDFA-A2CD-45AB-98D5-756162A1A4B0Q28079849-80205905-CCCC-411B-9D7E-939576DC58C6Q33890811-D049B635-F1A3-4142-BD20-E288B76BAE0AQ35782729-7AB252D5-5927-4918-B413-DA3410C1811CQ35932559-22DC7A46-141E-4F88-AF3C-2C6297FD2D74Q36550275-CA51FF80-8C91-4C40-8FFA-3D434EB08DCCQ38376243-E02C37D4-7FEB-4126-B845-B8BD3D8B8D14Q38587097-CBB8ACD6-C88B-4432-8B28-B3D594D73D13Q38649250-6ED51ACC-BD92-4C5A-A4E5-EA8EDAED4B33Q38689189-D919796E-1D53-48AB-8E3C-F6EDF7DD2792Q38702260-495353AE-78CB-48E7-A640-4D2A4A1CCC46Q38802810-8CC63FFE-55FF-4998-ACB7-35C5E03D7C4FQ38824034-4FB65B42-C157-4EB3-91CC-603E7D132FA2Q38827756-A166B4FF-0558-4D2B-BA5A-966CE4878941Q38857523-54DD2124-555D-4A4F-ACDD-048E28DFD4E8Q38966029-6F737609-7010-40D9-97D3-3508D1D871FAQ38987110-E68A8A6E-A451-4CC2-AFED-769DD9B79158Q39415439-6EAA8CC1-B86D-4D01-A17E-60006609E2DD
P2860
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Rationale, design, and baselin ...... f lixisenatide versus placebo.
@en
type
label
Rationale, design, and baselin ...... f lixisenatide versus placebo.
@en
prefLabel
Rationale, design, and baselin ...... f lixisenatide versus placebo.
@en
P2093
P50
P1476
Rationale, design, and baselin ...... f lixisenatide versus placebo.
@en
P2093
Brian Claggett
ELIXA Investigators
Eldrin F Lewis
Francesca Lawson
Jean-Claude Tardif
Jeffrey L Probstfield
Kenneth Dickstein
Lars V Køber
Marc A Pfeffer
P304
631-638.e7
P356
10.1016/J.AHJ.2015.02.002
P407
P577
2015-02-12T00:00:00Z